Marico Limited Plans ₹2.62 Billion Skinetiq Investment

Marico Limited has entered agreements for a ₹2.62 billion investment that will give its unit a 75% stake in Skinetiq, expanding the company’s international beauty and wellness portfolio in 2026. The transaction matters because Skinetiq will be absorbed by Marico South East Asia Corporation, which operates in Vietnam.

What is Marico Limited buying in Skinetiq?

Marico is acquiring a 75% shareholding in Skinetiq through agreements announced on February 9, 2026. Reuters reported that the deal is valued at ₹2.62 billion and that a Marico unit will purchase the stake.

The available information does not disclose Skinetiq’s revenue, profitability, product range, geography, transaction closing date, or the terms attached to the remaining 25% holding. Marico has described the arrangement as a strategic investment rather than disclosing full operating or financial details in the material provided.

The acquisition adds Skinetiq to Marico’s international structure. Marico South East Asia Corporation, the company’s Vietnam operation, absorbed the Beauty X acquisition in 2025 and the Skinetiq acquisition in 2026. This places both acquired businesses within the same regional operating platform.

The announcement follows Marico’s stated approach of building a new-age portfolio through staged acquisitions with a path to full ownership. The 75% Skinetiq stake is consistent with that structure, although the source does not specify any timeline, valuation mechanism, or contractual route for Marico to acquire the minority stake.

Why is the Skinetiq deal important for Marico?

The Skinetiq investment is important because it extends Marico’s international expansion through a majority-controlled acquisition while retaining a local operating structure. The company operates in global beauty and wellness categories, making the deal relevant to its stated category focus.

Marico Limited is the listed Indian parent, incorporated in October 1988 and headquartered in Mumbai. Its shares trade under BSE code 531642 and NSE symbol MARICO. The company’s international operations are conducted through local subsidiaries rather than directly through the listed parent.

The group’s international network includes Marico Bangladesh Limited, identified as a material subsidiary, Marico South East Asia Corporation in Vietnam, and Marico South Africa. The use of the Vietnam subsidiary for Skinetiq indicates that the transaction sits within Marico’s South East Asian business rather than its Indian operations.

Marico has not provided financial guidance related to the Skinetiq transaction in the supplied information. As a result, the immediate measurable facts for investors are the ₹2.62 billion deal value, the 75% stake being acquired, and the placement of the business within Marico South East Asia Corporation.

What are the key facts about the transaction?

The transaction involves a ₹2.62 billion investment for a 75% stake in Skinetiq, based on Marico’s February 9, 2026 announcement. The following table separates the disclosed facts from details that have not been provided.

The deal value is an acquisition outlay, not revenue or a reported operating expense. The source does not state how the investment will be funded, whether it includes contingent consideration, or whether it requires regulatory or other closing conditions.

The minority shareholding left outside Marico’s proposed 75% purchase may be relevant to governance and future ownership, but no specific rights or future purchase arrangement have been disclosed. Investors therefore cannot infer the final ownership structure or full cost of ownership from the available announcement.

How has Marico’s business performed before this investment?

Marico’s reported operating trends show growth in both its India and international businesses before the Skinetiq investment. In a company update, Marico said its India business recorded underlying volume growth of 8%, described as a seven-year high, while its international business achieved 20% constant-currency growth, described as a 14-year high.

The same update reported two-year compound annual growth rates of 10% for volume, 23% for revenue, and 17% for profit after tax. These figures indicate that the group had reported growth across demand, sales and earnings measures, although the provided material does not state the precise reporting period for those two-year calculations.

A directors’ report also said business volumes grew 8% during the year, while referring to the international business. That disclosure supports the relevance of overseas operations in Marico’s broader growth profile, though it does not quantify the contribution of individual markets or subsidiaries.

The Skinetiq transaction comes after Beauty X was absorbed by Marico South East Asia Corporation in 2025. Taken together, the two additions show that the Vietnam platform has become a vehicle for Marico’s regional portfolio development.

How could the deal affect investors and operations?

For investors, the disclosed transaction creates a clearly identifiable ₹2.62 billion capital commitment and gives Marico control of a 75% stake in Skinetiq. Its eventual financial effect on consolidated revenue, margins or profit cannot be calculated from the provided information because Skinetiq’s financial data and transaction accounting have not been disclosed.

The deal also reinforces Marico’s reliance on local subsidiaries for international expansion. Marico Bangladesh Limited, Marico South East Asia Corporation and Marico South Africa operate as regional businesses, allowing the parent to manage overseas activities through market-specific entities.

For industry operations, the transaction adds another acquisition to Marico’s beauty and wellness portfolio. The source provides no details on changes to employees, suppliers, customers, product distribution, manufacturing, or local communities, so no operational impact on those groups can be confirmed.

Marico has not disclosed a direct public statement on expected synergies, cost savings or integration milestones in the material supplied. The available official information is limited to the agreements, the stake size and the investment value, making the transaction structure more visible than its near-term earnings impact.

Conclusion

Marico’s planned ₹2.62 billion acquisition of a 75% stake in Skinetiq adds a majority-controlled business to its international portfolio and assigns it to Marico South East Asia Corporation in Vietnam. The transaction follows the 2025 absorption of Beauty X into the same regional unit and is consistent with Marico’s staged acquisition approach.

The next points to watch are the closing of the Skinetiq transaction, any disclosure on its financial contribution and the terms governing the remaining 25% stake. Marico’s future earnings updates may also provide evidence on whether the investment contributes to the international business, which recently reported 20% constant-currency growth.